Nitric oxide synthases and atrial fibrillation

Frontiers in Physiology

Volumn 3 APR, Issue , 2012, Pages

  Bonilla, Ingrid M ^a,b   Sridhar, Arun ^c   Györke, Sandor ^b,d   Cardounel, Arturo J ^b,d   Carnes, Cynthia A ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

^d THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Atrial fibrillation; Electrophysiology; Nitric oxide synthase; Oxidative stress; Therapeutics

Indexed keywords

EID: 84866302820     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2012.00105     Document Type: Article

References (60)

1. Ahern, G. P., Hsu, S. F., Klyachko, V. A., and Jackson, M. B. (2000). Induction of persistent sodium current by exogenous and endogenous nitric oxide. J. Biol. Chem. 275, 28810-28815.
2. Ahmmed, G. U., Xu, Y., Hong, D. P., Zhang, Z., Eiserich, J., and Chiamvimonvat, N. (2001). Nitric oxide modulates cardiac Na(+) channel via protein kinase A and protein kinase G. Circ. Res. 89, 1005-1013.
3. Asada, K., Kurokawa, J., and Furukawa, T. (2009). Redox- and calmodulin-dependent S-nitrosylation of the KCNQ1 channel. J. Biol. Chem. 284, 6014-6020.
4. Balligand, J. L., Ungureanu-Longrois, D., Simmons, W. W., Pimental, D., Malinski, T. A., Kapturczak, M., Taha, Z., Lowenstein, C. J., David-off, A. J., and Kelly, R. A. (1994). Cytokine-inducible nitric oxide synthase (iNOS) expression in cardiac myocytes. Characterization and regulation of iNOS expression and detection of iNOS activity in single cardiac myocytes in vitro. J. Biol. Chem. 269, 27580-27588.
5. Barouch, L. A., Harrison, R. W., Skaf, M. W., Rosas, G. O., Cappola, T. P., Kobeissi, Z. A., Hobai, I. A., Lemmon, C. A., Burnett,A. L., O'Rourke, B., Rodriguez, E. R., Huang, P. L., Lima, J. A., Berkowitz, D. E., and Hare, J. M. (2002). Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms. Nature 416, 337-339.
6. Bedi, M., McNamara, D., London, B., and Schwartzman, D. (2006). Genetic susceptibility to atrial fibrillation in patients with congestive heart failure. Heart Rhythm 3, 808-812.
7. Billman, G. E., Nishijima, Y., Belevych, A. E., Terentyev, D., Xu, Y., Haizlip, K. M., Monasky, M. M., Hiranandani, N., Harris, W. S., Gyorke, S., Carnes, C. A., and Janssen, P. M. (2010). Effects of dietary omega-3 fatty acids on ventricular function in dogs with healed myocardial infarctions: in vivo and in vitro studies. Am. J. Physiol. Heart Circ. Physiol. 298, H1219-H1228.
8. Cai, H., Li, Z., Goette, A., Mera, F., Honeycutt, C., Feterik, K., Wilcox, J. N., Dudley, S. C. Jr., Harrison, D. G., and Langberg, J. J. (2002). Downregulation of endocardial nitric oxide synthase expression and nitric oxide production in atrial fibrillation: potential mechanisms for atrial thrombosis and stroke. Circulation 106, 2854-2858.
9. Campbell, D. L., Stamler, J. S., and Strauss, H. C. (1996). Redox modulation of L-type calcium channels in ferret ventricular myocytes. Dual mechanism regulation by nitric oxide and S-nitrosothiols. J. Gen. Physiol. 108, 277-293.
10. Chen, C. A., Wang, T. Y., Varadharaj, S., Reyes, L. A., Hemann, C., Talukder, M. A., Chen, Y. R., Druhan, L. J., and Zweier, J. L. (2010). S-glutathionylation uncouples eNOS and regulates its cellular and vascular function. Nature 468, 1115-1118.
11. Dobrev, D., and Nattel, S. (2011). New insights into the molecular basis of atrial fibrillation: mechanistic and therapeutic implications. Cardiovasc. Res. 89, 689-691.
12. Fatini, C., Sticchi, E., Genuardi, M., Sofi, F., Gensini, F., Gori, A. M., Lenti, M., Michelucci, A., Abbate, R., and Gensini, G. F. (2006). Analysis of minK and eNOS genes as candidate loci for predisposition to non-valvular atrial fibrillation. Eur. Heart J. 27, 1712-1718.
13. Gallo, M. P., Malan, D., Bedendi, I., Biasin, C., Alloatti, G., and Levi, R. C. (2001). Regulation of cardiac cal-cium current by NO and cGMP-modulating agents. Pflugers Arch. 441, 621-628.
14. Gensini, F., Padeletti, L., Fatini, C., Sticchi, E., Gensini, G. F., and Michelucci, A. (2003). Angiotensin-converting enzyme and endothelial nitric oxide synthase polymorphisms in patients with atrial fibrillation. Pacing Clin. Electrophysiol. 26, 295-298.
15. Giusti, B., Gori, A. M., Marcucci, R., Sestini, I., Saracini, C., Sticchi, E., Gensini, F., Fatini, C.,Abbate, R., and Gensini, G. F. (2007). Role of C677T and A1298C MTHFR,A2756G MTR and -786 C/T eNOS gene polymorphisms in atrial fibrillation susceptibility. PLoS ONE 2, e495.
16. Goette, A., Hammwohner, M., Bukowska, A., Scalera, F., Martens-Lobenhoffer, J., Dobrev, D., Ravens, U., Weinert, S., Medunjanin, S., Lendeckel, U., and Bode-Boger, S. M. (2012). The impact of rapid atrial pacing on ADMA and endothelial NOS. Int. J. Cardiol. 154, 141-146.
17. Gomez, R., Caballero, R., Barana, A., Amoros, I., Calvo, E., Lopez, J. A., Klein, H., Vaquero, M., Osuna, L., Atienza, F., Almendral, J., Pinto, A., Tamargo, J., and Delpon, E. (2009). Nitric oxide increases cardiac IK1 by nitrosylation of cysteine 76 of Kir2.1 channels. Circ. Res. 105, 383-392.
18. Gomez, R., Nunez, L., Vaquero, M., Amoros, I., Barana, A., de, P. T., Macaya, C., Maroto, L., Rodriguez, E., Caballero, R., Lopez-Farre, A., Tamargo, J., and Delpon, E. (2008). Nitric oxide inhibits Kv4.3 and human cardiac transient outward potassium current (Ito1). Cardiovasc. Res. 80, 375-384.
19. Han, W., Fu, S., Wei, N., Xie, B., Li, W., Yang, S., Li, Y., Liang, Z., and Huo, H. (2008). Nitric oxide over-production derived from inducible nitric oxide synthase increases cardiomyocyte apoptosis in human atrial fibrillation. Int. J. Cardiol. 130, 165-173.
20. Hanna, I. R., Heeke, B., Bush, H., Brosius, L., King-Hageman, D., Dudley, S. C. Jr., Beshai, J. F., and Langberg, J. J. (2006). Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction. Heart Rhythm 3, 881-886.
21. Harling, L., Rasoli, S., Vecht, J. A., Ashrafian, H., Kourliouros, A., and Athanasiou, T. (2011). Do antioxidant vitamins have an antiarrhythmic effect following cardiac surgery? A meta-analysis of randomised controlled trials. Heart 97, 1636-1642.
22. Haywood, G. A., Tsao, P. S., von der Leyen, H. E., Mann, M. J., Keeling, P. J., Trindade, P. T., Lewis, N. P., Byrne, C. D., Rickenbacher, P. R., Bishopric, N. H., Cooke, J. P., McKenna, W. J., and Fowler, M. B. (1996). Expression of inducible nitric oxide synthase in human heart failure. Circulation 93, 1087-1094.
23. Hu,Y. F., Chen,Y. C., Cheng, C. C., Higa, S., Chen,Y. J., and Chen, S. A. (2009). Fluvastatin reduces pulmonary vein spontaneous activity through nitric oxide pathway. J. Cardiovasc. Electro-physiol. 20, 200-206.
24. Kim, Y. M., Guzik, T. J., Zhang, Y. H., Zhang, M. H., Kattach, H., Ratnatunga, C., Pillai, R., Channon, K. M., and Casadei, B. (2005). A myocardial Nox2 containing NAD(P)H oxidase contributes to oxidative stress in human atrial fibrillation. Circ. Res. 97, 629-636.
25. Kirstein, M., Rivet-Bastide, M., Hatem, S.,Benardeau,A.,Mercadier,J. J.,and Fischmeister, R. (1995). Nitric oxide regulates the calcium current in isolated human atrial myocytes. J. Clin. Invest. 95, 794-802.
26. Komatsu, T., Tachibana, H., Sato, Y., Ozawa, M., Kunugida, F., Orii, M., and Nakamura, M. (2009). Longterm efficacy of upstream therapy using angiotensin-converting enzyme inhibitors and statins in combination with antiarrhythmic agents for the treatment of paroxysmal atrial fibrillation. Int. Heart J. 50, 465-476.
27. Komatsu, T., Tachibana, H., Sato, Y., Ozawa, M., Kunugita, F., and Nakamura, M. (2011). Long-term efficacy of upstream therapy with lipophilic or hydrophilic statins on antiarrhythmic drugs in patients with paroxysmal atrial fibrillation: comparison between atorvastatin and pravastatin. Int. Heart J. 52, 359-365.
28. Lenaerts, I., Holemans, P., Pokreisz, P., Sipido, K. R., Janssens, S., Heidbuchel, H., and Willems, R. (2011). Nitric oxide delays atrial tachycardia-induced electrical remodelling in a sheep model. Europace 13, 747-754.
29. Li, J., Xia, W., Feng, W., and Qu, X. (2012). Effects of rosuvastatin on serum asymmetric dimethylarginine levels and atrial structural remodeling in atrial fibrillation dogs. Pacing Clin. Electrophysiol.
30. Malan, D., Levi, R. C., Alloatti, G., Marcantoni, A., Bedendi, I., and Gallo, M. P. (2003). Cyclic AMP and cyclic GMP independent stimulation of ventricular calcium current by peroxynitrite donors in guinea pig myocytes. J. Cell Physiol. 197, 284-296.
31. Mayyas, F., Sakurai, S., Ram, R., Rennison, J. H., Hwang, E. S., Castel, L., Lovano, B., Brennan, M. L., Bibus, D., Lands, B., Barnard, J., Chung, M. K., and Van Wagoner, D. R. (2011). Dietary omega3 fatty acids modulate the substrate for post-operative atrial fibrillation in a canine cardiac surgery model. Cardiovasc. Res. 89, 852-861.
32. Mihm, M. J., Yu, F., Carnes, C. A., Reiser, P. J., McCarthy, P. M., Van Wagoner, D. R., and Bauer, J. A. (2001). Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 104, 174-180.
33. Musialek, P., Lei, M., Brown, H. F., Paterson, D. J., and Casadei, B. (1997). Nitric oxide can increase heart rate by stimulating the hyperpolarization-activated inward current, I(f). Circ. Res. 81, 60-68.
34. Negi, S., Shukrullah, I., Veledar, E., Bloom, H. L., Jones, D. P., and Dudley, S. C. (2011). Statin therapy for the prevention of atrial fibrillation trial (SToP AF trial). J. Cardiovasc. Electrophysiol. 22, 414-419.
35. Nishijima, Y., Sridhar, A., Bonilla, I., Velayutham, M., Khan, M., Terentyeva, R., Li, C., Kuppusamy, P., Elton, T. S., Terentyev, D., Gyorke, S., Zweier, J. L., Cardounel, A. J., and Carnes, C. A. (2011). Tetrahy-drobiopterin depletion and NOS2 uncoupling contribute to heart failure-induced alterations in atrial electrophysiology. Cardiovasc. Res. 91, 71-79.
36. Nunez, L., Vaquero, M., Gomez, R., Caballero, R., Mateos-Caceres, P., Macaya, C., Iriepa, I., Galvez, E., Lopez-Farre, A., Tamargo, J., and Delpon, E. (2006). Nitric oxide blocks hKv1.5 channels by S-nitrosylation and by a cyclic GMP-dependent mechanism. Cardiovasc. Res. 72, 80-89.
37. Rajasekaran, N. S., Firpo, M. A., Milash, B. A., Weiss, R. B., and Benjamin, I. J. (2008). Global expression profiling identifies a novel biosignature for protein aggregation R120GCryAB cardiomyopathy in mice. Physiol. Genomics 35, 165-172.
38. Reilly, S. N., Jayaram, R., Nahar, K., Antoniades, C., Verheule, S., Channon, K. M., Alp, N. J., Schotten, U., and Casadei, B. (2011). Atrial sources of reactive oxygen species vary with the duration and substrate of atrial fibrillation: implications for the antiarrhythmic effect of statins. Circulation 124, 1107-1117.
39. Savelieva, I., Kakouros, N., Kourliouros, A., and Camm, A. J. (2011). Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention. Europace 13, 308-328.
40. Schotten, U., Verheule, S., Kirchhof, P., and Goette, A. (2011). Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol. Rev. 91, 265-325.
41. Schulze, F., Carter, A. M., Schwedhelm, E., Ajjan, R., Maas, R., von Holten, R. A., Atzler, D., Grant, P. J., and Boger, R. H. (2010). Symmetric dimethylarginine predicts all-cause mortality following ischemic stroke. Atherosclerosis 208, 518-523.
42. Shiroshita-Takeshita, A., Brundel, B. J., Burstein, B., Leung, T. K., Mitamura, H., Ogawa, S., and Nattel, S. (2007). Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure. Cardiovasc. Res. 74, 75-84.
43. Shiroshita-Takeshita, A., Brundel, B. J., Lavoie, J., and Nattel, S. (2006). Prednisone prevents atrial fibrillation promotion by atrial tachycardia remodeling in dogs. Cardiovasc. Res. 69, 865-875.
44. Suenari, K., Chen, Y. C., Kao, Y. H., Cheng, C. C., Lin, Y. K., Kihara, Y., Chen, Y. J., and Chen, S. A. (2011). Eicosapentaenoic acid reduces the pulmonary vein arrhythmias through nitric oxide. Life Sci. 89, 129-136.
45. Taglialatela, M., Pannaccione, A., Iossa, S., Castaldo, P., and Annunziato, L. (1999). Modulation of the K(+) channels encoded by the human ether-a-gogo-related gene-1 (hERG1) by nitric oxide. Mol. Pharmacol. 56, 1298-1308.
46. Tamargo, J., Caballero, R., Gomez, R., and Delpon, E. (2010). Cardiac electrophysiological effects of nitric oxide. Cardiovasc. Res. 87, 593-600.
47. Umar, S., and van der Laarse, A. (2010). Nitric oxide and nitric oxide synthase isoforms in the normal, hypertrophic, and failing heart. Mol. Cell. Biochem. 333, 191-201.
48. Usui, M., Matsuoka, H., Miyazaki, H., Ueda,S.,Okuda,S.,and Imaizumi,T. (1998). Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sci. 62, 2425-2430.
49. Van Wagoner, D. R. (2008). Oxidative stress and inflammation in atrial fibrillation: role in pathogenesis and potential as a therapeutic target. J. Cardiovasc. Pharmacol. 52, 306-313.
50. Vaziri, N. D.,Wang, X. Q., Ni, Z. N., Kivlighn, S., and Shahinfar, S. (2002). Effects of aging and AT-1 receptor blockade on NO synthase expression and renal function in SHR. Biochim. Biophys. Acta 153-161.
51. Vejlstrup, N. G., Bouloumie, A., Boesgaard, S., Andersen, C. B., Nielsen-Kudsk, J. E., Mortensen, S. A., Kent, J. D., Harrison, D. G., Busse, R., and Aldershvile, J. (1998). Inducible nitric oxide synthase (iNOS) in the human heart: expression and localization in congestive heart failure. J. Mol. Cell. Cardiol. 30, 1215-1223.
52. Winlaw, D. S., Smythe, G. A., Keogh, A. M., Schyvens, C. G., Spratt, P. M., and Macdonald, P. S. (1994). Increased nitric oxide production in heart failure. Lancet 344, 373-374.
53. Xia, Y., and Zweier, J. L. (1997). Superoxide and peroxynitrite generation from inducible nitric oxide synthase in macrophages. Proc. Natl. Acad. Sci. U.S.A. 94, 6954-6958.
54. Yagi, S.,Akaike, M.,Aihara, K., Ishikawa, K., Iwase, T., Ikeda, Y., Soeki, T., Yoshida, S., Sumitomo-Ueda, Y., Matsumoto, T., and Sata, M. (2010). Endothelial nitric oxide synthase-independentprotectiveactionof statin against angiotensin II-induced atrial remodeling via reduced oxidant injury. Hypertension 55, 918-923.
55. Yamashita, T., Sekiguchi, A., Iwasaki, Y. K., Date, T., Sagara, K., Tanabe, H., Suma, H., Sawada, H., and Aizawa, T. (2010). Recruitment of immune cells across atrial endocardium in human atrial fibrillation. Circ. J. 74, 262-270.
56. Young-Xu, Y., Jabbour, S., Goldberg, R., Blatt, C. M., Graboys, T., Bilchik, B., and Ravid, S. (2003). Useful-ness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am. J. Cardiol. 92, 1379-1383.
57. Zhang, H., Limphong, P., Pieper, J., Liu, Q., Rodesch, C. K., Christians, E., and Benjamin, I. J. (2012). Glutathione-dependent reductive stress triggers mitochondrial oxidation and cytotoxicity. FASEB J. 26, 1442-1451.
58. Zhang, X., Min, X., Li, C., Benjamin, I. J., Qian, B., Zhang, X., Ding, Z., Gao, X., Yao, Y., Ma, Y., Cheng, Y., and Liu, L. (2010). Involvement of reductive stress in the cardiomyopathy in transgenic mice with cardiac-specific overexpression of heat shock protein 27. Hypertension 55, 1412-1417.
59. Ziolo, M. T., and Bers, D. M. (2003). The real estate of NOS signaling: location,location,location. Circ. Res. 92, 1279-1281.
60. Zweier, J. L., Chen, C. A., and Druhan, L. J. (2011). S-glutathionylation reshapes our understanding of endothelial nitric oxide synthase uncoupling and nitric oxide/reactive oxygen species-mediated signaling. Antioxid. Redox Signal. 14, 1769-1775